Effects of maternal docosahexaenoic acid supplementation on brain development and neurodevelopmental outcomes in breastfed preterm infants: a preschool follow-up of a randomized clinical trial (MOBYDIckPS)
When a child is born very prematurely, the brain is not fully mature. Several crucial stages of brain development occur in the weeks following birth. Better nutrition, adapted to the needs of the premature baby, especially with docosahexaenoic acid (DHA, an omega-3 found in large quantities in the brain), could have a positive impact on the brain development and neurodevelopment of children born very prematurely.
The MOBYDIckPS study proposes long-term follow-up of preterm infants enrolled in the study. The MOBYDIck study, a Canadian multi-centric study, involves mothers of very premature infants who have taken either a DHA supplement or a placebo during the neonatal period and who then provide their breast milk for the study. Thus, in the mothers randomized to the DHA group, the breast milk was enriched with DHA at a dose similar to that transmitted by the placenta at the end of pregnancy (thus making it possible to meet the needs of the very preterm child). We now have a unique opportunity to determine whether supplementation with a high dose of DHA is a strategy to improve the development of the very preterm infant.
- Dr. Mireille Guillot, Associate researcher, Reproduction, Maternal and Child Health Axis, CHUL
- CHU Québec: Dr. Isabelle Marc, Dr. Georges Caouette and Dr. Célia Matte-Gagné
- CHU Sainte-Justine: Dr. Ibrahim Mohamed
- CHU Sherbrooke: Dr. Alyssa Morin
- Jewish General Hospital: Dr. Julie Bartholomew
- Montreal Children’s Hospital: Dr. François Olivier
- Research Centre CHU de Québec-Université Laval
- Neurodevelopment and mental health
- Perinatal, neonatal and obstetrics